Lv5
1490 积分 2021-11-21 加入
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
1个月前
已完结
Use of venetoclax in t(11;14) positive relapsed/refractory multiple myeloma: A systematic review
1个月前
已完结
Precision medicine for multiple myeloma: The case for translocation (11;14)
1个月前
已完结
Biomarker-directed therapy in multiple myeloma
1个月前
已完结
Venetoclax in biomarker‐selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety
1个月前
已完结
Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency
1个月前
已完结
Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency
1个月前
已关闭
A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma
2个月前
已完结
[Guideline for the diagnosis and management of multiple myeloma-related renal impairment (2024 version)]
3个月前
已完结
[Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)]
3个月前
已完结
皖公网安备34019202002308
